B+
Bull case
20%
Probability
Target price
$2.97
Analysis reference price unavailable
Analysis 2025-11-24 · RankAlpha Sentiment AI
FDMT
4D Molecular TherapeuticsFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment AIMost likely
B
Base case
60%
Probability
Target price
$1.98
Analysis reference price unavailable
Analysis 2025-11-24 · RankAlpha Sentiment AI
B-
Bear case
20%
Probability
Target price
$0.50
Analysis reference price unavailable
Analysis 2025-11-24 · RankAlpha Sentiment AI
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2025-11-24
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
0.0
Score
AI commentary
Investor focus is binary: positive readouts or partnership news could trigger strong rallies, while cash‑runway or negative clinical headlines drive rapid downside. Filings and recent investor releases emphasize active programs and continued R&D spend, keeping near‑term sentiment cautious and event‑driven.
RankAlpha Sentiment AI - 2025-11-24
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
-eventClinical readouts for lead AAV programsHigh impact
Upcoming early‑stage trial readouts or cohort updates that would materially re‑rate the stock on positive efficacy/safety signals (company Q3 2024 results and investor release).
-catalystFinancing / dilution riskHigh impact
Ongoing R&D spend implies a meaningful chance of near‑term financing; equity raises would be dilutive and pressure the share price.
-catalystPlatform validation via partnership/licensingHigh impact
A material licensing or partnership agreement for the capsid/platform would de‑risk programs and likely produce multi‑quarter valuation upside.
Recommendation
N/A
No formal recommendation provided.
As of 2025-11-24 • Updated nightlySource: Internal modelMethodology